Mismatch Repair (MMR) gene alteration and BRAF V600E mutation are potential predictive biomarkers of immune checkpoint inhibitors in MMR-deficient colorectal cancer

CONCLUSION: BRAF V600E mutation, MLH1 and/or PMS2 loss, as well as age >65 years and liver metastasis may be predictive of duration of ICI response in MMR-deficient CRC patients. Larger cohorts are needed to confirm our findings.IMPLICATIONS FOR PRACTICE: This results of this original research article reveals clinically important biomarkers that potentially predict immune checkpoint inhibitor response in mismatch repair deficient colorectal cancer patients.PMID:33631043 | DOI:10.1002/onco.13741

Source: The Oncologist - February 25, 2021 Category: Cancer & Oncology Authors: Ibrahim Halil Sahin Subir Goyal Yoanna Pumpalova Mohamad B Sonbol Satya Das Sigurdis Haraldsdottir Daniel Ahn Kristen K Ciombor Zhengjia Chen Amber Draper Jordan Berlin Tanios Bekaii-Saab Gregory B Lesinski Bassel F El-Rayes Christina Wu Source Type: research